The FDA's AI Device Registry Just Crossed 1,500 Entries—But the Fastest-Growing Cancer Tools Aren't on the List

The U.S. Food and Drug Administration has now authorized more than 1,500 AI-enabled medical devices for marketing, marking a significant milestone in the integration of artificial intelligence into clinical care. Oncology applications are expanding particularly rapidly, spanning cancer detection, diagnosis, prognosis, pathology analysis, and radiation therapy planning—yet a notable regulatory gap is emerging between the narrow, task-specific algorithms that carry FDA clearance and the broader AI tools increasingly transforming everyday practice.

Recent Oncology AI Approvals Signal Accelerating Adoption

The FDA's growing device list includes several notable oncology approvals from 2025 and 2026. Perimeter Medical Imaging AI's Claire OCT System received Premarket Approval on March 3, 2026, for breast cancer margin assessment using optical coherence tomography with AI-based computer-aided detection. RevealDx's RevealAI-Lung secured 510(k) clearance on January 30, 2026, providing malignancy similarity scores for incidentally detected lung nodules on CT imaging.

ArteraAI Prostate received De Novo authorization in July 2025, analyzing digital histopathology to estimate 10-year risks of distant metastasis and prostate cancer-specific mortality. Therapixel's MammoScreen 4 also gained FDA clearance in July 2025 for AI-assisted mammogram interpretation. Earlier approvals include Paige Prostate, which received De Novo authorization in 2021 for identifying suspicious areas in digitized prostate biopsy slides, and MD Anderson Cancer Center's Radiation Planning Assistant, cleared in 2023 for radiation treatment planning.

The 2026 additions to the FDA list also include InferCare RECIST and multiple AI-enabled radiology and radiation therapy systems, demonstrating the breadth of applications now entering the regulatory pipeline through 510(k) clearance, De Novo authorization, and Premarket Approval pathways.

The Regulatory Paradox: Narrow Approvals, Broad Clinical Impact

Despite this regulatory momentum, a significant tension is emerging in how AI tools are actually being deployed in oncology practice. Dr. Roupen Odabashian, an oncologist at Abbotsford Regional Hospital and Cancer Centre and founder of MeDucation AI, highlighted this gap: "The tools that are transforming practice fastest are precisely the ones with the least oversight, while the narrow, locked, single-task algorithms carry the approvals."

This observation points to a fundamental challenge in AI medical device regulation: the FDA's current framework is designed for specific, locked algorithms performing defined tasks, yet many of the AI tools reshaping clinical workflows are general-purpose platforms that may fall outside traditional device categories. The result is what Dr. Odabashian characterizes as a regulatory arbitrage where specialized point solutions navigate formal approval pathways while broader AI platforms potentially transform practice with less oversight.

Implications Across the Cancer Care Continuum

For healthcare providers, the expanding roster of FDA-cleared AI tools offers new capabilities spanning the cancer care continuum—from screening and detection through prognostic risk stratification to treatment planning. However, clinicians must navigate between regulated narrow-task algorithms and unregulated general-purpose AI tools, creating practical challenges in determining which technologies to adopt and how to integrate them into clinical workflows.

For health tech companies, the FDA's device list validates commercial pathways for task-specific AI medical devices while simultaneously highlighting opportunities for broader platforms that may face less regulatory scrutiny. This creates competitive tension between companies pursuing formal clearances for specialized applications and those developing more flexible, general-purpose clinical AI systems.

For patients, the proliferation of AI-enabled cancer technologies holds promise for earlier detection, more accurate risk stratification, and optimized treatment planning—though the clinical impact on real-world outcomes remains an open question as these tools are adopted faster than outcome data can accumulate.

Sources

1. FDA Lists More Than 1,500 AI-Enabled Medical Devices as Oncology Applications Expand - OncoDaily